ThromboGenics raises €77.8 million in share placement

Thursday 29 March 2012

ThromboGenics NV, a Belgian company developing ophthalmic medicines, has raised €77.8 million in a private placement of its shares arranged by KBC Securities NV, Merrill Lynch International and Petercam NV.

Full text available to subscribers only. Click here for information on subscribing to MedNous.

Location

Belgium